Amgen publishes positive new multiple myeloma data for Xgeva

Amgen has announced the publication of new clinical study data that adds to the body of evidence supporting the efficacy of its multiple myeloma therapy Xgeva.

Data from the phase III '482 study has been published in The Lancet Oncology, showing that Xgeva was able to meet its clinical goals in the trial, which was the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted.

Xgeva successfully met its primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to the first on-study skeletal-related event in patients with multiple myeloma. Its safety profile was also consistent with known trends.

The drug is the first fully human monoclonal antibody that binds to and neutralises RANK ligand, a protein essential for the formation, function and survival of osteoclasts. It was recently approved in the US for the prevention of skeletal-related events in multiple myeloma, based on the positive findings of the '482 study.

Dr David Reese, senior vice-president of translational sciences and oncology at Amgen, said: "The bone-specific effects combined with the renal safety profile demonstrate that Xgeva is an important new alternative to the current standard of care for the prevention of skeletal-related events in patients with multiple myeloma."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.